Is Lithium a Strong QT Prolonger?
No, lithium is not classified as a strong QT-prolonging medication and does not appear on major cardiology society lists of high-risk QT-prolonging drugs. 1, 2
Evidence from Guideline Classifications
The European Heart Journal's comprehensive 2014 guideline on psychotropic medication-induced arrhythmia risk stratifies drugs into three categories (Class A, Class B, and Class B*—the highest risk). Lithium is notably absent from all QT-prolonging drug classifications in this authoritative guideline, indicating it is not recognized as a clinically significant QT-prolonging agent. 1
Similarly, the American College of Cardiology/American Heart Association/Heart Rhythm Society QT-prolonging drug catalogs do not list lithium among known QT-prolonging medications. 2
What Lithium Actually Does to the ECG
While lithium does produce electrocardiographic changes, these are mechanistically distinct from the dangerous repolarization delays seen with true QT-prolonging drugs:
- T-wave inversion is the most frequently reported ECG finding with lithium, not QT prolongation. 3
- Lithium can cause sinus node dysfunction, sinoatrial blocks, and PR prolongation (conduction abnormalities), but QT prolongation is rarely reported and not a primary concern. 3
- The electrical changes from lithium are dependent on both duration of treatment and serum lithium level, suggesting they are concentration-related rather than intrinsic pharmacologic effects on repolarization. 3
Critical Context: The Escitalopram Case Report
A 2010 case report describing QTc prolongation in a patient who overdosed on both lithium and escitalopram is sometimes misinterpreted. 4 However, escitalopram is a known QT-prolonging SSRI (particularly at high doses), whereas the lithium co-ingestion was incidental. 2 The European Heart Journal explicitly identifies citalopram and escitalopram as QT-prolonging agents in patients with pre-existing cardiovascular disease. 2
The Thioridazine Interaction
One 1984 case report described torsades de pointes in a patient receiving lithium plus thioridazine 800 mg daily. 5 Thioridazine is a Class B antipsychotic with the highest QT-prolongation risk (25–30 ms mean increase) and carries an FDA black-box warning*—it is the culprit drug in this scenario, not lithium. 2, 6
Practical Clinical Implications
- Lithium does not require the same QTc monitoring protocols mandated for true QT-prolonging psychotropics (baseline ECG, serial follow-up ECGs at 7–15 days, electrolyte surveillance for hypokalemia/hypomagnesemia). 2
- When lithium is combined with genuine QT-prolonging agents (e.g., thioridazine, haloperidol, macrolides, fluoroquinolones), the QT risk derives from the other medication, not the lithium. 1, 2
- Standard lithium monitoring focuses on renal function, thyroid function, and serum lithium levels—not QTc intervals—unless the patient has independent cardiac risk factors or is receiving concurrent QT-prolonging drugs. 3
Common Pitfall to Avoid
Do not conflate lithium's well-documented effects on cardiac conduction (sinus node dysfunction, AV block) with QT prolongation; these are separate electrophysiologic phenomena with different arrhythmia risks. 3 Lithium's conduction abnormalities can cause bradycardia, which is itself a risk factor for drug-induced torsades when other QT-prolonging agents are present, but lithium does not directly prolong repolarization. 1, 2